Overview

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Status:
ENROLLING_BY_INVITATION

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

This is a nonrandomized, open-label, multicenter rollover study for patients who received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib study.

Phase:

PHASE2

Details

Lead Sponsor:

Taiho Oncology, Inc.

Treatments:

Fulvestrant
futibatinib